**Efficacy and Mechanism of Action of CXCR4 Inhibition in B16 OVA Melanoma Model**

Ruchi Saxena¹, Yan Wang², James W. Mier¹

¹Beth Israel Deaconess Medical Center, Department of Medicine, Boston, USA; ²X4 Pharmaceuticals, Cambridge, USA.

**Background**

The chemokine receptor CXCR-4 has been found to be over-expressed in a variety of cancers and promotes cancer cell proliferation and metastasis, possibly by activating pro-survival signals that render cancer cell resistant to immune attack. Blockade of immune inhibitory pathways is emerging as an important therapeutic approach for the treatment of cancer. In our previous studies, we demonstrated that combination of a CXCR4 antagonist with an anti-angiogenesis agent axitinib relieved myeloid-derived suppressor cell (MDSC) mediated immunosuppression and suppressed HIF-2α expression, which resulted in synergistic antitumor effects in 786-O and A498 RCC xenografts. To further study the CXCR4 mechanism of action in an immune-proficient background, we investigated the activity of a CXCR4 antagonist (X4-136) in a syngeneic mouse tumor model. As the current murine models for RCC do not share the same genetic alterations with the human disease, the B16-OVA model was selected for this study. The CXCR4 antagonist was tested in combination with axitinib or with checkpoint inhibitors which are part of the standard of care in managing melanoma in clinic.

**Results**

**Robust Inhibition of B16 Melanoma Growth by X4-136 as Single Agent and in Combination.**

**Modulation of Immune-Phenotype in Tumor Micro-Environment**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>CD8+ cells</th>
<th>CD8+ cells</th>
<th>Treg cells</th>
<th>MDCs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>100%</td>
<td>100%</td>
<td>10%</td>
<td>20%</td>
</tr>
<tr>
<td>X4-136</td>
<td>80%</td>
<td>80%</td>
<td>20%</td>
<td>15%</td>
</tr>
<tr>
<td>4+X4-136</td>
<td>90%</td>
<td>90%</td>
<td>10%</td>
<td>10%</td>
</tr>
</tbody>
</table>

Reduction of immune-suppressive environment in TME. Single cell suspensions were prepared from tumor tissues by treating with collagenase and analyzed for various immune cell populations using flow cytometry.

**Western Blot Analysis of Tumor Lysates: Induction of p27 and Reduction of Cyclin D1 Expression**

Western blot analysis revealed a decrease in Cyclin D1 expression and an increase in p27 expression in tumors treated with X4-136.

**Suppression of HIF-2α Activity and Inhibition of Cyclin D1 and Invasion**

![Graph showing suppression of HIF-2α activity and inhibition of Cyclin D1 and Invasion](image)

Reduction of cyclin D1 and induction of p27 by X4-136. X4-136 inhibits HIF-2α response element. B16-oVa in normoxic and hypoxic conditions were transiently transfected with pIRES-luc and pRL-luc and incubated with different concentrations of X4-136 for 24h. Luciferase activity was measured using dual luciferase assay kit.

**Conclusion**

- X4-136 alone potently inhibited growth of the B16-Ova murine melanoma.
- Enhanced activity was observed when X4-136 was added to either axitinib or to anti-CTLA-4/PD-L1 treatments.
- The anti-tumor activities were associated with the reduction of immuno-suppressive MDSCs and Treg populations and the increase in immuno-stimulatory CD8+/Perforin+ cells in the tumor microenvironment.
- X4-136 reduces the invasive capability of B16-Ova cells as well.